US › Healthcare

Rallybio Corp (RLYB)

US · Healthcare · Biotechnology

$16.28-2.95%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$43.7M

EPS

$-1.09

EPS estimate

$-1.28

EPS came in at -1.09 against a street estimate of -1.28 — a beat of 14.8%.

Key statistics

Market cap

$88.8M

P/E

2.1

Forward P/E

0.0

P/B

0.95

Book value

$17.81

EPS (TTM)

$8.01

52-week high

$17.57

52-week low

$3.67

50-day MA

$16.80

200-day MA

$12.18

Beta

-0.71

Analyst view

with an average price target of $8.00.

Shareholding

Insiders

24.54%

Institutions

86.14%

Largest institutional holders

Fund	Stake
ADAR1 Capital Management LLC	17.44%
FMR Inc	14.96%
Viking Global Investors LP	9.87%
TPG GP A, LLC	7.13%
Nantahala Capital Management, LLC	7.09%
Pivotal bioVenture Partners Investment Advisor LLC	5.66%
Renaissance Technologies Corp	3.76%
Vanguard Capital Management, LLC	3.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rallybio Corp — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.